OI Ljubljana
Eng

doc. dr. Maja Čemažar, univ. dipl. biol.

Nazivi in funkcije

  • zdravstveni sodelavec specialist
  • docentka
  • višja znanstvena sodelavka
  • znanstvena svetnica

Izobrazba

Naziv / vrsta izobrazbeUstanova / zavod / krajLeto  Področje
diplomaUniverza v Ljubljani, Biotehniška fakulteta 1992biologija
magisterijUniverza v Ljubljani, Medicinska fakulteta 1996tumorska biologija
doktoratUniverza v Ljubljani, Medicinska fakulteta1998temeljne medicinske vede
podoktorski študijGray Cancer Institute, Velika Britanija1999-2001vaskularna biologija
višja znanstvena sodelavkaUniverza v Ljubljani 2000radioterapija in onkologija
docentkaUniverza v Ljubljani, Biotehniška fakulteta 2004molekularna biologija
znanstvena svetnicaUniverza v Ljubljani, Medicinska fakulteta2005radioterapija in onkologija

        

Področja dela

Maja Čemažar je raziskovalka, ki se na Onkološkem inštitutu v Ljubljani že 14 let ukvarja s translacijskimi raziskavami v onkologiji. Kot vodja raziskovalnega projekta je aktivna na področju eksperimentalne onkologije, kjer raziskuje biomedicinske aplikacije elektroporacije. Glavno področje njenega dela je uporaba elektroporacije za ciljan vnos citostatikov v tumorje, kjer so raziskave že v klinični fazi poskusov. V zadnjem času pa se ukvarja tudi z elektrogensko terapijo, ki ima velike možnosti za prenos v kliniko.

Pedagoško je aktivna kot mentorica magistrandom in doktorandom ter kot predavateljica na dodiplomskem študiju na Univerzi v Novi Gorici, Univerzi na Primorskem in na podiplomskem študiju biomedicine Univerze v Ljubljani.  

Članstvo v strokovnih združenjih

  • Slovensko imunološko društvo
  • European Society for Therapuetic Radiology and Oncology
  • Društvo za medicinsko in biološko tehniko Slovenije
  • International Union Against Cancer
  • European School of Oncology
  • American Association for Cancer Research
  • Slovensko društvo za laboratorijske živali, podpredsednica
  • European Bioelectrochemical society
  • British Association for Cancer Research

Priznanja in nagrade

  • 1996 Krkina nagrada za raziskovalno delo
  • 2000 Young Investigator Award, 11th International Conference Chemical Modifiers Treatment Series Tumour Physiology and Cancer Treatment, Banff, Alberta, Canada, October 5–7, 2000  

Pomembne objave

  • Serša G, ČEMAŽAR M, Miklavčič D. Antitumor effectiveness of electrochemotherapy with cis-diamminedichloroplatinum(II) in mice. Cancer Res 1995; 55: 3450–5.
  • Miklavčič D, Beravs K, Šemrov D, ČEMAŽAR M, Demšar F, Serša G. The importance of electric field distribution for effective in vivo electroporation of tissues. Biophys J 1998; 74: 2152–8.
  • Mir LM, Glass LF, SERŠA G, Teissie J, Domenge C, Miklavčič D, Jaroszeski MJ, Orlowski S, Reintgen DS, Rudolf Z, Belehradek M, Gilbert R, Rols MP, Belehradek JJr, Bachaud JM, DeConti R, Štabuc B, Čemažar M, Coninx P, Heller R. Effective treatment of cutaneous and subcutaneous malignant tumors by electrochemotherapy. Brit J Cancer 1998; 77: 2336–42.
  • Serša G, Kranjc S, ČEMAŽAR M. Improvement of combined modality therapy with cisplatin and radiation using electroporation of tumors. Int J Radiat Oncol Biol Phys 2000; 46: 1037–41.
  • ČEMAŽAR, M., Parkins, C. S., Holder, A. L., Chaplin, D. J., Tozer, G. M. and Serša, G. Electroporation of human microvascular endothelial cells: evidence for an anti-vascular mechanism of electrochemotherapy. British Journal of Cancer, 2001; 84: 565–70.
  • ČEMAŽAR M, Miklavcic D, Mir LM, Belehradek JJr, Bonnay M, Fourcault D, Sersa G. Electrochemotherapy of tumours resistant to cisplatin: a study in a murine tumour model. Eur J Cancer 2001; 37/9: 1166–1172.
  • Tozer GM, Prise VE, Wilson J, ČEMAŽAR M, Shan S, Dewhrist MW, Barber PR, Vojnovic B, Chaplin DJ. Mechanisms associated with tumour vascular shut-down induced by combretatstatin A-4 phosphate: Intravital microscopy and measurement of vascular permeability. Cancer Res, 2001; 61: 6413–22.
  • ČEMAŽAR M, Serša G, Wilson J, Tozer GM, Hart SL, Grošel A, Dachs G. Effective gene transfer to solid tumours using different non-viral gene delivery techniques: electroporation, liposomes and integrin-targeted vector. Cancer Gene Ther 2002; 9: 399–406.
  • ČEMAŽAR M, Auersperg M, Ščančar J, Srebotnik Kirbiš I, Pogačnik A, Serša G. Schedule dependent interaction between vinblastine and cisplatin in EAT tumours in mice. J Pharm Exp The 2002: 302: 337–43.
  • ČEMAŽAR M, Grošel A, Glavač D, Kotnik V, Skoberne M, Kranjc S, Mir LM, Andre F, Opolon P, Serša G. Effects of electrogenetherapy with p53wt combined with cisplatin on survival of human tumor cell lines with different p53 status. DNA Cell Biol 2003; 22: 765–75.
  • ČEMAŽAR M, Wilson I, Dachs GU, Tozer G, Serša G. Direct visualization of electroporation-assisted in vivo gene delivery to tumors using intravital microscopy – spatial and time dependent distribution. BMC Cancer 2004; 4:81. doi:10.1186/1471-2407-4-81
  • Tozon N, Kodre V, Serša G, ČEMAŽAR M. Effective treatment of perianal tumours in dogs with electrochemotherapy. Anticancer Res 2005; 25: 839-46.
  • ČEMAŽAR M, Wilson I, Prise VE, Bell KM, Hill SA, Tozer GM. The endothelin B (ETB) receptor agonist IRL 1620 is highly vasoconstrictive in two syngeneic rat tumour lines: potential for selective tumour blood flow modification. British Journal of Cancer 2005; 93: 98-106.
  • Grabner S, Modec B, CEMAŽAR M, Bukovec N. Crystal structures and cytotoxicity of isopropylamine Pt(II) complexes: a trinuclear squarato-bridges [Pt3(2-C4O4)3(H2NPri)6]x3H2O and a mononuclear cis-[Pt(NO3)2(H2NPri)2]. J Inorg Biochem 2005; 99: 1465-71.
  • ČEMAŽAR M, Golzio M, Rols MP, Serša G, Teissie J. Electrically-assisted nucleic acid delivery in vivo: Where do we stand? Review. Current Pharmaceutical Design 2006; 12: 3817-25.
  • ČEMAŽAR M, Pavlin D, Kranjc S, GroŠel A, Mesojednik S, SerŠa G. Sequence and time dependence of transfection efficiency of electrically-assisted gene delivery to tumors in mice. Current Drug Delivery 2006, 3:77-81
  • ČEMAŽAR M, Golzio M, Escoffre JM, Couderc B, Serša G, Teissie J. In vivo imaging of tumour growth after electrochemotherapy with cisplatin. Biochem, Biophys Res Commun, 2006, 348: 997-1002.
  • Grabner S, ČEMAŽAR M, Bukovec N, Serša G. syntheses and cytotoxicity of Pt(II) complexes with Acyclovir. Acta Chim Slov 2006; 51: 153-6.
  • Snoj M, Rudolf Z, Paulin-Košir S, ČEMAŽAR M, Snoj R, Serša G. Long lasting complete response in melanoma treated by electrochemotherapy. EJC Suppl 2006; 4: 26-8.
  • Marty M, Serša G, Garbay JR, Gehl J, Collins CG, Snoj M, Billard V, Geertsen PF, Larkin JO, Miklavčič D, Pavlović I, Paulin-Kosir SM, ČEMAŽARemažar M, Morsli N, Soden DM, Rudolf Z, Robert C, O’Sullivan GC, Mir LM. Electrochemotherapy – an easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study. EJC Suppl 2006; 4: 3-13.
  • Kanthou C, Kranjc S, Serša G, Tozer GM, Zupanic A, ČEMAŽAR M. The endothelial cytoskeleton as a target of electroporation based therapies. Molecular Cancer Therapeutics, in press.
  • Grošel A, Serša G, Kranjc S, ČEMAŽAR M. Electrogene therapy with p53 of murine sarcomas alone or combined with electrochemotherapy using cisplatin. DNA Cell Biol 2006, in press.

 

 

© 2018 - Onkološki inštitut Ljubljana